Concepedia

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

Julie Boucau, Rockib Uddin, Caitlin Marino, James Regan, James P. Flynn, Manish C. Choudhary, Geoffrey Chen, Ashley Stuckwisch, Josh Mathews, May Y. Liew,

Clinical Infectious Diseases · 2022 · 93 citations · 8 references

DOIFull text

Open access

Concepts

Abstract

We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log10 copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.

References

8

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

New England Journal of Medicine · 2022 · 2.2K citations · Full text

, , +12

SARS-CoV-2 viral load is associated with increased disease severity and mortality

Jesse Fajnzylber, James Regan, Kendyll Coxen et al. · Nature Communications · 2020 · 979 citations · Full text

, , +9

Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections

Mark J. Siedner, Julie Boucau, Rebecca F. Gilbert et al. · JCI Insight · 2021 · 57 citations · Full text

, , +17

Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment

Aaron F. Carlin, Alex E. Clark, Antoine Chaillon et al. · Research Square · 2022 · 41 citations · Full text

, , +16

Duration of viable virus shedding in SARS-CoV-2 omicron variant infection

Julie Boucau, Caitlin Marino, James Regan et al. · medRxiv · 2022 · 34 citations · Full text

, , +17